"It is easy to get excited about NWBO; Investors are waiting for data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer."

$nwbo #dcvax #glioblastoma $mrk $bmy #immunotherapy

https://t.co/CVIUfMA0mE